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Background: Musashi2(Msi2)-Numb pathway de-regulation is a molecular mechanism underlying the transition of
chronic phase Ph + CML to deadly blast crisis, particularly in cases with a NUP98/HOXA9 fusion from a t(7;11)
(p15;p15). This study provides new insights on the mechanisms cooperating in driving MSI2 over-expression and
progression of Ph-positive CML.
Results: Herein we describe a t(7;11)(p15;p15) originating a NUP98 fusion with HOXA13, at 7p15, in a 39 year-old
man in blast crisis of Ph-positive CML. Both MSI2 and HOXA9 were evaluated by quantitative RT-PCR in our patient
and in a series of haematological malignancies. Up-regulation of both genes emerged only in the presence of
NUP98/HOXA13 gene fusion. However, over-expression of MSI2, but not HOXA9, was found in 2 cases of Ph + blast
crisis with additional chromosome aberrations other than t(7;11). To determine the mechanisms underlying MSI2
over-expression in our patient we performed Chromatin Immunoprecipitation and found that NUP98/HOXA13
fusion protein deregulates MSI2 gene by binding its promoter.
Conclusions: To the best of our knowledge, this is the first molecular characterization of NUP98/HOXA13
fusion in blast crisis of Ph + CML. Our findings suggest cooperative mechanisms of MSI2 over-expression
driven by HOXA proteins and strongly supports MSI2 as a prognostic marker and a candidate in target
treatment of CML.
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MSI2 gene (17q22) is a member of the Musashi (Msi)
family, which is well conserved during mammals evolution
and distributed in the stem cell compartment of neural [1],
hematopoietic [2], pancreatic [3] and epithelial tissues [4,5].
Two translocations involving MSI2 gene at 17q22 have
been described in myeloid malignancies [6,7] and more
than 50 point mutations have been reported in solid
tumors and cell lines (COSMIC database [8], cBioPortal
for Cancer Genomics [9]) [10]. Msi2 expression is acti-
vated by cooperation between HoxA9 and Meis1 in
Meis1-immortalized hematopoietic progenitors [11]. In
chronic myeloid leukemia (CML) Ito et al. [12] showed the
Nup98/HoxA9 fusion contributed to blast crisis through
HoxA9 homeodomain binding to the Msi2 promoter
resulting in gene over-expression, down-regulation of the* Correspondence: cristina.mecucci@unipg.it
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article, unless otherwise stated.Notch1 inhibitor Numb, and loss of the proliferation/
differentiation equilibrium in hematopoietic stem cells
(HSCs) [13]. De-regulation of the Musashi-Numb-Notch1
signaling axis is associated with poor prognosis in CML
[12], acute myeloid leukemia (AML) [14] and B-cell
acute lymphoblastic leukemia (B-ALL) [15]. In addition to
HOXA9, two genes of the HOXA cluster at 7p15, i.e.,
HOXA11 [16] and HOXA13 [17], rearrange with NUP98
in leukemia. All fusion transcripts contain the NUP98
N-terminal, with the FG/GLFG domains, that mediate both
RNA and protein transport, and the HOX homeodomain,
with its DNA binding ability [18]. Thus all these chimeric
proteins exhibit their oncogenic potential via transcriptional
activation of downstream genes [19]. Remarkably a single t
(7;11)(p15;p15) can produce more than one NUP98/HOXA
fusion [16]. We investigated MSI2 regulation in the first
case of Ph-positive CML in blast crisis with t(7;11) and
NUP98/HOXA13 fusion gene.ntral Ltd. This is an Open Access article distributed under the terms of the
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Patient
A 39 year-old man was referred to our department because
of leukocytosis, mild anemia, and thrombocytopenia
(WBC 180000/mmc, Hb 11.8 g/dl, PLT 130000/mmc)
associated with splenomegaly. Chronic Myeloid Leukemia
in Blast Crisis was diagnosed on peripheral blood and bone
marrow smears. Karyotype was 46,XY,t(9;22)(q34;q11)
[6]/46,XY,t(9;22)(q34;q11),t(7;11)(p15;p15) [9]. Hydroxyurea
therapy followed by Dasatinib 140 mg/day (40 days),
were unsuccessful. The patient did not respond to high-dose
ARA-C (3 g/m2/day, on days 1-3-5-7) and Daunorubicin
(50 mg/m2/day on days 1-3-5). Rescue chemotherapy
with Clofarabine (40 mg/m2/day on days 1–5) and
Gemtuzumab-Ozogamicin (3 mg/m2/day on day 6) in-
duced prolonged aplasia. Four months after diagnosis
the patient underwent unsuccessful bone marrow trans-
plantation from a HLA haploidentical brother.
Fluorescence In Situ Hybridization (FISH)
The t(7;11) at diagnosis was investigated by FISH with
RP11-348A20 (green) and CTD-3234 F16 (red) for NUP98
gene, RP1-170O19 (centromeric, green) and RP1-167 F23
(telomeric, red) for the HOXA cluster at 7p15. MSI2 gene
(17q22) was studied with genomic clones RP11-166P13,
RP11-226 M10, RP11-118E18 and RP11-13H16, oriented
from centromere to telomere. Analysis was performed with
fluorescence microscopy (Provis, Olympus, Italy) equipped
with a cooled CCD camera (Sensys-Photometrics, Tucson
AZ, USA) and a SmartCapture software (Vysis, Stuttgart,
Germany). Metaphase FISH (Figure 1a) showed a NUP98/
HOXA gene rearrangement and Interphase FISH (data not
shown) identified the fusion in 57% of nuclei.
Breakpoint cloning
Total RNA was extracted by Trizol reagent (Invitrogen,
Carlsbad, CA, USA) and retrotranscribed withThermoscript
(Invitrogen) according to the manufacturer’s protocol.
Nested or semi-nested-PCRs were performed to identify
the involved HOXA partner gene [18]. In testing for the
three HOXA genes primers were:
1. NUP98_1083F 5’-ggtaataccagcaccataggacag-3’ and
HOXA9_1036R 5’-tgtggcctgaggtttagagc-3’ or
HOXA9_736R 5’-cagttccagggtctggtgtt-3’ for the first
amplification round; NUP98_1252F
5’-cttactacatttggaagcac-3’ and HOXA9_736R or
HOXA9_708R 5’-gggcaccgctttttccgagt-3’ for the
second (NUP98: NM_00139131.3, HOXA9:
NM_001164603.1).
2. NUP98_1083F and HOXA11_837R 5’-
ctctcggatctggtacttggt-3’ for the first amplification
round and NUP98_1252F or HOXA11_837R for
the semi-nested PCR (HOXA11: NM_ 005523.5).3. NUP98_1083F and HOXA13_992R
5’-cctcctataggagctggcat-3’ for the first amplification
round and NUP98_1252F or NUP98_1400F
5’-acctgggactcttggaactg-3’ and HOXA13_992R for
semi-nested PCRs (HOXA13: NM_000522.4).
PCR products were sub-cloned into the pGEM-Teasy
vector (Promega, Madison, WI) and sequenced by Sanger’s
method (ABI 3500 Genetic Analyzer, Applyed Biosystems,
Foster City, CA). Molecular analysis revealed an in-
frame fusion transcript. NUP98/HOXA13 had 3885 bp
and a breakpoint between exon 16 (nt 2322) of NUP98
(NM_00139131.3) and exon 2 (nt 952) of HOXA13 gene
(NM_000522.4). Three splicing variants had the same
breakpoint but were lacking respectively NUP98 exon 11,
12 or 14 (which was out of frame) (Figure 1b and c).
Quantitative PCR
Since in silico analysis showed HOXA13 and HOXA9
homeodomains were very similar (75,4% of similarity; 57,9%
of identity, score: 274; analysis performed with EMBOSS
Matcher program 6.6.0 http://www.ebi.ac.uk/Tools/psa/
emboss_matcher/, matrix: BLOSUM80, gap penality: 14,
extended penality: 4), we hypothesized NUP98/HOXA13
could bindMSI2 promoter and tested whether HOXA9 was
involved in the present patient. qRT-PCR (LightCycler480,
Roche Diagnostics, Germany) was performed using
TaqMan assay probes (Applied Biosystems, Foster City, CA)
Hs00292670_m for MSI2 gene, Hs00365956_m1 for
HOXA9 and Hs00426284_m1 for HOXA13. Our CML in
blast crisis was compared with 41 cases of diverse haemato-
logical malignancies (13 blast crisis CML, 13 chronic phase
CML, 10 NPM1c+AML which over-express MSI2 [14,20]
and 5 Acute Promyelocytic Leukaemia) as well as 12 cases
of non-malignant diseases (wt). Reaction mixtures, of 25 μl
each, contained 12.5 μl of TaqMan Universal PCR Master
Mix (Applied Biosystems), 1.25 μl of the TaqMan assay
probe and 5 μl of cDNA (1/10 of RT product). Protocol
consisted of 2 minutes at 50°C for activation of AmpliTaq
Gold and 10 minutes at 95°C for DNA denaturation.
Amplification was performed with 45 cycles of 15 s at
95°C and 1 min at 61°C. All samples were tested in tripli-
cate. Amplification of the sequence of interest was normal-
ized to the average of two endogenous reference controls,
GUSB (Hs00939627_m1) and B2M (Hs00984230_m1) [21],
and compared to the expression of a Universal Human
Reference RNA (Stratagene, Cedar Creek, TX, USA).
Fluorescence data were analyzed with the software version
1.5 and Second Derivative Maximum method; gene ex-
pression was expressed as Cp (Crossing point) values.
Statistic significance for MSI2 expression was tested by
Mann–Whitney test (*p < 0.05/3). In the present case both
MSI2 and HOXA9 were over-expressed (Figure 2a, b and c).
Notably this over-expression emerged also using the
Figure 1 Molecular and cytogenetic studies. a) Metaphase FISH showed a rearrangement between NUP98 gene at 11p15 and the HOXA
cluster at 7p15. b) Breakpoint falls between NUP98 exon 16 and HOXA13 exon 2. Red triangles indicate in-frame splicing variants; yellow triangle
an out-of-frame variant. Sequence analysis confirmed the transcript. c) The fusion protein with NUP98 GLFG repeats and the HOXA13
homeodomain (HD).
Di Giacomo et al. Molecular Cytogenetics 2014, 7:42 Page 3 of 7
http://www.molecularcytogenetics.org/content/7/1/42two reference genes singularly [see Additional file 1].
No wild-type HOXA13 was found (data not shown). MSI2,
but not HOXA9, was significantly over-expressed also in
two other cases of Ph + blast crisis CML both harbouringadditional cytogenetic aberrations (BC1 and BC2 in
Figure 2a and b), with the following karyotypes: 46,
XY,t(9;22)(q34;q11) [8]/49-52,XY,idem,+8,+t(9;22)(q34;
q11),+13,+15,+21[cp6] (patient BC1), and 46XY,t(3;7)
Figure 2 Expression analysis. a) MSI2 and b) HOXA9 are over-expressed in the present patient with NUP98/HOXA13. BC1 and BC2: two other
cases of Ph + blast crisis CML with additional karyotypic aberrations over-expressing MSI2 but not HOXA9. Expression values were referred to the
average of two references. Fluorescence data were analyzed with the Second Derivative Maximum method; gene expression was expressed as Cp
(Crossing point) values. c) Significance for MSI2 expression was tested by Mann–Whitney test (*p < 0.05/3); values are expressed as means +/− SD;
AA. Additional aberrations.
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in these cases FISH excluded involvement of NUP98, the
HOXA cluster and MSI2 gene.
Chromatin Immunoprecipitation (ChIP)
Human MSI2 and HOXA9 genomic promoters were de-
duced using information provided by Web Promoter Scan
Service [22]. ChIP assays (EZ-ChIP, Millipore-Upstate, MA,
USA) were performed on 2x107 cryopreserved bonemarrow cells after cross-linking (1% formaldehyde), lysis
(SDS lysis buffer plus protease inhibitors) and sonication.
2×106 cells were pre-cleared and 1% kept as “input”.
Anti-NUP98 [2H10] (ab50610 Abcam) was used to recover
protein-DNA complexes. 3 μl of immunoprecipitated DNA
were amplified by semi-quantitative PCR with primers
for the hypothetical HOXA13 binding sites: MSI2_-842 F
(5’-GTGTTTGTGCAGGAGGGTCT-3’)/MSI2_-615R
(5’-CCCTCTCTAGTTCGCCCTCT-3’) and HOXA9_-1071
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(5’- AGTCAAATTCAACGCAGGATC-3’). The exponential
amplification conditions were controlled to obtain data
in a linear range of amplification. Data were confirmed
by qPCR using Brilliant II SYBR Green qPCR Master
Mix (Agilent Technologies, USA) and LightCycler480
(Roche Diagnostics, Germany). The crossing point (Cp)
determined the quantity of immunoprecipitated DNA
[23]. ChIP confirmed the binding of NUP98/HOXA13,
but not of wild-type NUP98, to both MSI2 and HOXA9
promoters in the present patient (Figure 3a and b).Figure 3 Chromatin Immunoprecipitation. NUP98/HOXA13 binds both M
sample and a non-malignant disease sample (wt). 1,5 μg of rat IgG (Millipore
used as negative controls. a) Semi-quantitative PCR showed an enrichment in
result; data are presented as fold increase relative to the control sample (wt) b
(for HOXA9) ChIP experiments is shown. The results shown are the mean ± S.E
binds both MSI2 and HOXA9 promoters. HOXA9 binds MSI2 promoter. Protein
transcription start site (TSS; +1), direction of transcription (flag), putative HOXConclusions
This study was important to enrich our knowledge on mo-
lecular events underlying the t(7;11)(p15;p15) in the blastic
crisis of Ph + CML. For the first time NUP98/HOXA13
has been identified in CML, although it was reported in
one case of AML [17] and one case of MDS [16]. The
pathogenetic role of NUP98/HOXA13 rearrangement in
the evolution in this case is emphasized by the absence
of transcript isoforms from alternative splicing, such as
NUP98/HOXA11 and all NUP98/HOXA9, as previously
reported [17]. As we excluded the presence of the wildSI2 and HOXA9 promoters. ChIP was performed on both NUP98/HOXA13
Normal Rat IgG Polyclonal Antibody) and No Antibody (not shown) were
NUP98/HOXA13 sample compared to controls. b) qPCR confirmed this
ased on the formula 2−ΔΔCp [23]. One out of three (for MSI2) or two
.M. (error bars) of two independent qPCR experiments. c) NUP98/HOXA13
structure: homeodomain (HD). Gene structure: exons (numbered boxes),
binding element 1 kb upstream of TSS (oval).
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expressed in malignant cells (Figure 2a, b and c) as a conse-
quence of NUP98/HOXA13 fusion. Notably, HOXA13,
fused to NUP98, up-regulated MSI2 both directly by bind-
ing to its promoter and indirectly by binding to the HOXA9
promoter, thus inducing a synergistic effect between the
two HOXA proteins (Figure 3c).
Over-expression of MSI2, but not HOXA9, emerged in
two other cases of Ph + blast crisis (BC1 and BC2, Figure 2a
and b) with additional cytogenetic rearrangements suggest-
ing that, in addition to HOXA9 and HOXA13, alternative
mechanisms may deregulate MSI2 in the presence of clonal
evolution and acute phase progression of Ph +CML.
In conclusion this study provided new insights on the
molecular heterogeneity of t(7;11)(p15;p15) in the blastic
crisis of Ph +CML. Our report suggests that HOXA13 can
bind to the promoter of MSI2 and may contribute to its ac-
tivation in a patient that harbors NUP98/HOXA13 fusion.
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